A Phase I/II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
R
Roberto Pili, MD
Primary Investigator
Overview
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Description
The purpose of this study is to identify the best dose of entiostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
renal cell carcinoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1609248502 (IUSCC-0574)
